Uncategorized

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more prior treatment regimens. The conditional approval by the National Medical Products Administration (NMPA) was based…

Debbie’s Dream Foundation: Curing Stomach Cancer shared on LinkedIn: “New Interview Alert! Our CEO, Andrea Eidelman, sat down with OncoDaily’s Editor-in-Chief, Gevorg Tamamyan, for a powerful conversation about the mission of Debbie’s Dream Foundation: Curing Stomach Cancer (DDF). In this interview, Andrea shares her inspiring journey from advocating for underprivileged children as an attorney to leading DDF in the global…

Gastric cancer (GC) is characterized with differentiation disorders, the precise mechanisms of which remain unknown. Our previous study showed that PHF10 exhibits oncogenic properties in GC, with its histological presentation indicating a potential role in the modulation of differentiation disorders in GC. This study reveals a significant upregulation of PHF10 in GC tissues, showing a…

Cancer With the Help of an AACR Grant Valerie O’Brien, PhD, is using her microbiology expertise to model and study gastric cancer development with early support from a Debbie’s Dream Foundation-AACR grant. As a graduate student at Washington University in St. Louis, Valerie O’Brien, PhD, studied chronic bacterial infections. Then, an opportunity to donate bone marrow…

Combination therapy with evorpacept (ALX148), trastuzumab (Herceptin), ramucirumab (Cyramza), and paclitaxel (TRP) meaningfully improved overall response rate (ORR) and duration of response (DOR) compared with TRP alone among those with previously treated HER2-positive advanced gastric cancer or gastroesophageal junction (GEJ) cancer, according to a press release on findings from the phase 2 ASPEN-06 trial (NCT05002127).1…

In 2011, a Chinese research team began visiting nearly 1000 villages in Shandong province to launch an unprecedented cancer prevention experiment. A simple breath test given to more than 180,000 people revealed that, like most populations around the world, more than half harbored the bacterium Helicobacter pylori in their guts. Famed for causing stomach inflammation…

“The National Institute for Health and Care Excellence (NICE) has recommended the use of the immunotherapy drug pembrolizumab (also known as Keytruda) as an option for people with advanced gastric cancer. The recommendation is for those with advanced gastric or gastro-oesophageal cancers that are inoperable or have spread to other parts of the body, and…

In a recent study published in The Lancet Public Health, researchers assessed cancer incidence and mortality trends in the United States (US). Previously, the authors reported an increased incidence of eight cancers over time in successively younger birth cohorts in the US. Besides, people born between 1965 and 1980 might have increased incidence rates of…

Dear Friends, I am writing to you with a heartfelt request for your support. My name is Chris Gomez, and I want to share my personal story and commitment to the mission of Debbie’s Dream Foundation: Curing Stomach Cancer (DDF). On December 12, 2020, my mother, Cristina Gomez, was diagnosed with stomach cancer. Alongside my…

Health officials are increasingly concerned about the rise of antibiotic-resistant infections, also known as ‘superbugs’. However, this month an Israel-based pharmaceutical company showed that we may be able to combat this threat. View Full Article